News Summary Seven new systems across Argonne and Los Alamos National Laboratories to be released, accelerating the ...

Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator ...

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...

Europe: Labcorp recently took a stake in SYNLAB, a big European lab company. This could be a way to test the waters and see ...

A merger would significantly change the competitive scene. With Quest and Labcorp being major players, their combination ...

Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for ...

Quest Diagnostics ( ($DGX) ) has released its Q3 earnings. Here is a breakdown of the information Quest Diagnostics presented to its investors.

Strong growth, raised guidance, and new partnerships signal continued momentum amid regulatory and cost headwinds.

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

The company’s diagnostic information services revenues increased 13.5% to $2.76 billion, with requisition volume growing 12.5% and revenue per requisition up 0.8%. Cash provided by operations surged ...

Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter. The provider of diagnostic ...